REGN vs. ROIV: Regeneron Pharmaceuticals vs. Roivant Sciences Stock Comparison

Company Profile

Regeneron Pharmaceuticals (REGN) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Regeneron Pharmaceuticals (REGN) has more than two decades of public-market history since April 2, 1991, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Regeneron Pharmaceuticals (REGN) reports 14.95%, ranking against industry peers normally.

Regeneron Pharmaceuticals (REGN) at 28.51% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Regeneron Pharmaceuticals (REGN) reports 40.46%, ranking against industry peers normally.

Profitability Metrics

Growth

Regeneron Pharmaceuticals (REGN) at 0.99% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Both Regeneron Pharmaceuticals (REGN) at 0.08 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Roivant Sciences (ROIV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Roivant Sciences (ROIV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Regeneron Pharmaceuticals (REGN) trades at 19.99 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.

Valuation Metrics